整形外科中的肽类:前景、证据与陷阱
该叙述性综述评估了肽类在整形外科各领域的应用证据,发现创面愈合证据最成熟但缺乏监管批准,瘢痕和美容领域人类数据有限,重建领域仍以临床前证据为主。作者指出商业宣传与证据间存在显著差距,呼吁开展标准化结局的随机对照试验。
要点
- 创面愈合领域肽类证据最成熟,抗菌与再生肽已进入II期及早期III期试验。
- 美容肽类人类数据有限,商业宣传与现有证据差距尤为显著。
- 重建领域肽类应用仍以临床前证据为主,缺乏充分有力的随机对照试验。
核心结论
- 肽类在整形外科各领域显示出前景,但目前缺乏稳健的临床验证,商业宣传与证据间的差距在美容实践中尤为明显。
研究设计与样本
- 叙述性综述,检索PubMed、EMBASE、CENTRAL、Scopus和Google Scholar从建库至2026年5月,采用OCEBM框架和临床就绪度进行证据分级。
主要发现
- 创面愈合领域证据最成熟,抗菌和再生肽已进入II期及早期III期试验,但缺乏整形外科适应症的监管批准。
- 瘢痕调节肽已进入早期临床评估,美容肽积累了一定的人类数据。
- 重建应用仍主要依赖临床前证据支持。
- 局限性包括样本量小、结局指标异质、随访时间短以及美容文献中制造商资助的研究。
关键数值与推荐
- 创面愈合:抗菌与再生肽已进入II期及早期III期试验。
- 瘢痕调节肽:已进入早期临床评估。
- 美容肽:积累了有限的人类数据。
- 重建应用:仍以临床前证据为主。
临床怎么用
- 整形外科医生在向患者提供咨询时应保持批判性知情态度,审慎看待商业宣传。
- 整形外科医生具有独特优势,可牵头开展所需试验以建立更广泛采用的证据基础。
局限性
- 纳入研究样本量小、结局指标异质、随访时间短。
- 美容文献中存在制造商资助的研究。
- 转化障碍包括生物半衰期短、组织穿透性差、监管不确定以及缺乏充分有力的标准化结局随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Bioactive peptides are increasingly investigated as therapeutic adjuncts in plastic surgery. Despite increasing scientific, commercial, and patient interest, the current evidence base remains heterogeneous and predominantly preclinical. This review aimed to evaluate the current and emerging applications of peptides in plastic surgery, focusing on wound healing, reconstructive surgery, scar modulation, aesthetic practice, safety, regulation, and translational barriers. METHODS: A narrative review was performed using PubMed, EMBASE, CENTRAL, Scopus, and Google Scholar from database inception to May 2026. Evidence was synthesized narratively and graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) framework alongside clinical readiness. RESULTS: Evidence was most mature in wound healing, where antimicrobial and regenerative peptides have progressed to phase II and early phase III trials, although regulatory approval for plastic surgical indications remains lacking. Scar modulation peptides have entered early clinical evaluation, and aesthetic peptides have accumulated modest human data. In contrast, reconstructive applications remain supported predominantly by preclinical evidence. Limitations included small sample sizes, heterogeneous outcome measures, short follow-up, and manufacturer-funded studies in the aesthetic literature. Translational barriers included short biological half-life, poor tissue penetration, regulatory uncertainty, and the lack of adequately powered randomized controlled trials with standardized outcome measures. CONCLUSIONS: Peptides show promise but currently lack robust clinical validation across plastic surgical domains. The disparity between commercially marketed claims and current evidence is particularly pronounced in aesthetic practice. Plastic surgeons should maintain a critically informed approach when counseling patients and are uniquely positioned to lead the trials required to establish the evidence base for broader adoption.
引用
- Lau HX, Sharma SC. Peptides in Plastic Surgery: Promise, Evidence, and Pitfalls. Ann Plast Surg. 2026. PMID: 42758872. doi:10.1097/SAP.0000000000004895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。